Unlocking the power of genetically modified mesenchymal stem cells

Unlocking the power of genetically modified mesenchymal stem cells


Kyttaro Therapeutics is a development-stage platform technology company with a unique patent portfolio in clinical applications of genetically modified MSCs for treatment of diseases with a high, unmet clinical need.


Kyttaro’s expertise and intellectual property are based on 15 years of research and development in Germany and around the world in cutting-edge applications for MSC Alpha-1 Antitrypsin (MSC-AAT), MSC Cytokines (MSC-Cyt) and MSC-Klotho.

Kyttaro Therapeutics is a development-stage platform technology company with a unique patent portfolio in clinical applications of genetically modified MSCs for treatment of diseases with a high, unmet clinical need.

Kyttaro’s expertise and intellectual property are based on 15 years of research and development in Germany and around the world in cutting-edge applications for MSC Alpha-1 Antitrypsin (MSC-AAT), MSC Cytokines (MSC-Cyt) and MSC-Klotho.

Kyttaro was founded with a singular vision:

Kyttaro was founded with a singular vision:




To improve the quality of care for patients suffering from diseases with high unmet medical need and orphan drug status, by developing unique treatments based on genetically modified mesenchymal stem cells.

To improve the quality of care for patients suffering from diseases with high unmet medical need and orphan drug status, by developing unique treatments based on genetically modified mesenchymal stem cells.

Select applications

Select applications


Based on 58 Patents on MSC-AAT, MSC-Cyt, and MSC-Klotho

Based on 58 Patents on MSC-AAT, MSC-Cyt, and MSC-Klotho

Learn More About the Science
  • Graft Vs. Host Disease (GvHD)

  • Type 1 Diabetes

    (preclinical evaluation underway)

  • Combination with CAR-T Cell Therapy

    (preclinical evaluation underway)

  • Kidney Disease

    (preclinical evaluation underway)

  • Acute Myocardial Infarction

    (preclinical evaluation underway)

  • Neurodegenerative Diseases (Alzheimer’s Disease, Dementia, etc.)

     

  • Graft Vs. Host Disease (GvHD)

  • Type 1 Diabetes

    (preclinical evaluation underway)

  • Combination with CAR-T Cell Therapy

    (preclinical evaluation underway)

  • Kidney Disease

    (preclinical evaluation underway)

  • Acute Myocardial Infarction

    (preclinical evaluation underway)

  • Neurodegenerative Diseases (Alzheimer’s Disease, Dementia, etc.)

     

Next steps


Kyttaro is poised to commence clinical trials in Europe and the US for GvHD applications, with others to follow. We invite interested partners to contact us for more details.

Next steps

Next steps


Kyttaro is poised to commence clinical trials in Europe and the US for COVID-19 and GvHD applications. We invite interested partners to contact us for more details.

Kyttaro is poised to commence clinical trials in Europe and the US for GvHD applications, with others to follow. We invite interested partners to contact us for more details.